Regulatory T cells and anti-inflammatory cytokine networks (Treg/AICN)

Regulatory T cells (Tregs) are a specialized subpopulation of T cells, primarily defined by the expression of the transcription factor FoxP3, that are essential for maintaining immune self-tolerance and preventing autoimmune diseases (Fontenot et al., 2003, Nature Immunology). They function within a complex network of anti-inflammatory cytokines, most notably Interleukin-10 (IL-10), Transforming Growth Factor-beta (TGF-beta), and IL-35, which collectively suppress the activation and proliferation of effector T cells and antigen-presenting cells (Vignali et al., 2008, Nature Reviews Immunology). In the context of autoimmune disorders and organ transplantation, therapeutic efforts focus on expanding Treg populations or enhancing their suppressive cytokine output to dampen unwanted immune responses (Shevach, 2009, Immunity). Conversely, in oncology, Tregs are often recruited by tumors to create an immunosuppressive microenvironment that shields malignant cells from the immune system, making them a target for depletion or functional inhibition via checkpoint inhibitors (Togashi et al., 2019, Nature Reviews Clinical Oncology). The balance of this network is critical, as insufficient Treg activity leads to systemic inflammation, while excessive activity can impair host defense and anti-tumor surveillance (Sakaguchi et al., 2008, Cell).

Other names

TregsSuppressor T cellsTreg-mediated suppression networkAnti-inflammatory cytokine milieuImmune tolerance network

Therapeutic strategies involve the expansion of CD4+CD25+FoxP3+ regulatory T cells to restore tolerance in autoimmunity, or the inhibition/depletion of these cells to enhance anti-tumor immunity. This is achieved through the modulation of IL-2 signaling, CTLA-4 blockade, or the induction of suppressive cytokines like IL-10 and TGF-beta (Sakaguchi et al., 2008, Cell; Shevach, 2009, Immunity).